On February 26, 2024, Pacira BioSciences, Inc. and Charles A. Reinhart, III, the Company?s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024. The Company has commenced a search for a successor to Mr. Reinhart. The Company and Mr. Reinhart also agreed to enter into a Consulting Agreement to be effective October 1, 2024, pursuant to which Mr. Reinhart will provide transition services to the Company from October 1, 2024 until June 30, 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.42 USD | -1.47% | +8.12% | -12.80% |
May. 10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.80% | 1.37B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024